Clinical Trials Arena April 18, 2024
KOLs who spoke to GlobalData prior to AAN unanimously stated high hopes for PRX-002 in terms of modifying disease progression.
There are currently no marketed disease-modifying therapies (DMTs) for Parkinson’s disease (PD).
Key opinion leaders (KOLs) previously interviewed by GlobalData, a leading data and analytics company, identified the lack of DMTs as the largest unmet need in PD treatment.
At the American Academy of Neurology (AAN) 2024 annual meeting, Roche presented positive four-year results from a six-year open-label extension of its Phase II ‘PASADENA’ trial evaluating the efficacy of prasinezumab (PRX-002), a potentially PD-modifying monoclonal antibody.
In Roche’s Phase II PASADENA trial, 316 participants received an intravenous infusion of either PRX-002 or placebo at 1,500mg (low dose cohort) or 4,500mg...
Today's Sponsors
Today's Sponsor